EcoDrugPlus

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSPVAG00000011461
Gene Symbol: MPL
1 Cross references
186 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSPVAG00000005093
Gene Symbol: MLST8
1 Cross references
201 Possible Orthologues:

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSPVAG00000013328
Gene Symbol: NQO1
1 Cross references
195 Possible Orthologues:

Nadph Oxidase 4

Ensembl ID : ENSPVAG00000010422
Gene Symbol: NOX4
1 Cross references
151 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSPVAG00000010382
Gene Symbol: NFE2L2
1 Cross references
216 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSPVAG00000000788
Gene Symbol: NPC1L1
1 Cross references
189 Possible Orthologues:

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPVAG00000006958
Gene Symbol: PIM1
1 Cross references
245 Possible Orthologues:

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPVAG00000007647
Gene Symbol: PIM2
1 Cross references
115 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPVAG00000010666
Gene Symbol: PIM3
1 Cross references
217 Possible Orthologues:

Rar Related Orphan Receptor C

Ensembl ID : ENSPVAG00000008917
Gene Symbol: RORC
1 Cross references
382 Possible Orthologues:

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSPVAG00000009983
Gene Symbol: RELA
1 Cross references
199 Possible Orthologues:

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSPVAG00000004298
Gene Symbol: ROS1
1 Cross references
124 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).